The White House Council of Economic Advisers has finally put a number on Most Favored Nation drug pricing: close to $600 billion over ten years. The bigger story for manufacturers is buried in the detail. The voluntary agreements now reach past government programs into the commercial market, and the decision to sign is tangled up with tariffs and the mandatory Medicare models.
Last month the Council of Economic Advisers (CEA) published Savings from Most-Favored-Nation (MFN) Drug Pricing Policy, its most detailed case yet for the Most Favored Nation drug pricing framework. The $600 billion figure is built to make MFN look settled. It pays to ask how that number is put together, because the assumptions inside it are the same ones that decide your own exposure. And for the first time, the report is specific about how far the voluntary manufacturer agreements actually reach.
This analysis is based on the CEA’s May 2026 report. Read the full report →
The headline numbers
The savings estimate splits into separate channels, each flowing from a different part of the voluntary framework. Four figures do most of the work.
Run the same model against the 2025 novel-drug cohort, which the CEA views as closer to today’s pipeline, and prospective savings climb to $733 billion. That gap is the tell: the biggest figure in the report is also the most sensitive to its inputs.
Where the savings come from
MFN is not one policy but several linked mechanisms, and the savings sit in different places. Each one covers ground we’ve written about before.
Prospective MFN (future launches)
Manufacturers commit to launching new drugs in the US at prices comparable to a basket of high-income countries, measured on a net, all-market average basis. This is the largest bucket, and the one that reaches furthest, because it runs into the commercial market too.
Medicaid MFN (existing drugs)
Existing single-source drugs are offered to state Medicaid programs at MFN prices wherever the current net price sits above the benchmark, delivered through supplemental rebates. Our GENEROUS explainer walks through this structure in detail.
Direct-to-consumer (TrumpRx.gov)
Discounted cash-pay pricing for self-administered drugs, with the deepest cuts on GLP-1s and fertility medicines. Injectable GLP-1s, at roughly $1,000 to $1,350 a month, fall to $350; the drug cost of a standard IVF cycle drops from about $5,187 to $2,996.
Medicare GLP-1 coverage
A time-limited GLP-1 “Bridge” demonstration from July 2026, with a $50 flat monthly co-pay, moving into the CMMI BALANCE model. Expanded obesity coverage becomes affordable because the prices were cut first.
The part that reaches commercial
Most of the MFN conversation has stayed on government programs: Medicaid through GENEROUS, Medicare through the proposed GLOBE and GUARD models. The voluntary agreements go further, and the report is unusually clear about it. For existing drugs, manufacturers make MFN prices available to Medicaid and through the TrumpRx.gov cash-pay channel. For future launches the commitment is broader: prospective MFN, in the report’s words, “applies across all markets in the U.S., inclusive of the private insurance market.” In practice a manufacturer’s blended net price across every US channel, commercial included, has to land at or below the MFN benchmark.
That is the line worth sitting with. Commercial is where most branded margin is made, and the mandatory CMS models never touch it. They only reach government payers. The voluntary agreement, for anything launched from here on, pulls MFN into the commercial book as well. Seventeen manufacturers have signed so far, and the Administration expects most makers of sole-source brands to follow. So the deepest and widest pricing concession in the entire framework is the one companies are signing up to of their own accord.
How the CEA defines “MFN”
The definitions matter more than the headline, because they decide which of your products get caught and by how much. The method mirrors the GENEROUS construct: a price net of all discounts, rebates and concessions (including portfolio-wide clawbacks like the UK’s VPAG); an eight-country basket of the G-7 excluding the US, plus Denmark and Switzerland; and the second-lowest of those prices, PPP-adjusted, as the reference.
Taking the second-lowest price rather than an average limits the pull of outliers, but it also hands negotiators a discrete, targetable number to move. That design choice, and the way a Method I benchmark then stays fixed for years once set, is where a lot of the strategy lives. We picked those details apart in The Fine Print.
Sign, or hold out?
If the voluntary commitment is this broad, why sign it? Because it does not sit on its own. It sits against the Administration’s Section 232 pharmaceutical tariffs, announced in April 2026 at up to 100% on patented drugs and active ingredients. The tariff schedule is the reason companies are at the table: a manufacturer with an MFN pricing agreement drops to a 0% Section 232 rate from late September 2026 through 20 January 2029. An onshoring agreement on its own gets you to 20%; doing both gets you to zero.
Look at that end date. Tariff relief for signing runs to 20 January 2029, inauguration day. That timing turns a pricing decision into a bet on the political calendar.
Sign the voluntary agreement
Zero Section 232 tariffs through January 2029, plus access to the TrumpRx channel.
The cost: future launches priced to MFN net across all US channels, commercial included. That is the broadest concession on the table.
The bet: relief runs only to the end of the term, codification into law is far from certain, and a later administration or the courts may dilute or drop MFN. You take on broad, near-term exposure in exchange for tariff cover and the chance the framework proves temporary.
Hold out
Keep commercial pricing freedom, and avoid anchoring future launches to MFN across every channel.
The cost: exposure to Section 232 tariffs (up to 100%, or 20% with an onshoring deal), and you are still captured by the mandatory Medicare models, GLOBE on Part B and GUARD on Part D, on government business regardless.
The bet: tariffs are absorbable or negotiable through onshoring, the mandatory models get narrowed or struck down in court, and commercial freedom is worth more than tariff relief.
Neither route escapes MFN. Signing means broad, voluntary MFN across all channels with tariff relief attached. Holding out means tariffs on top of the government-payer models you cannot opt out of anyway. The real question is which exposure a company would rather carry, and how long it thinks the current framework lasts. Tariffs, onshoring commitments and where you choose to manufacture all fold into the same decision now, a theme we picked up in Redefining Ex-US Success. And because a Method I benchmark locks in at launch, a choice made in the next few months can shape a product’s position well into the next presidential term.
Whichever way a company leans, the work is the same: model both branches side by side. On the sign side, the blended net-price gap to the second-lowest PPP-adjusted benchmark across the full channel mix, commercial included, and what closing that gap does to margin. On the hold-out side, the cost of tariffs stacked on top of GLOBE and GUARD. These stopped being separate questions, which is the wider point behind The End of Two Silos: government and commercial, US and ex-US, tariffs and benchmarks now move together. If the framework also succeeds in lifting reference-country prices, the risk travels outward to those markets too, as we set out in MFN and the Shift of Risk for Ex-US Markets.
The bottom line
The CEA’s report is advocacy with a real model behind it, and the $600B headline will carry the political argument. For manufacturers, the more useful disclosure is how far the voluntary agreements reach (into commercial, for every future launch) and how neatly the tariff relief for signing lines up with the electoral cycle.
That turns a pricing question into a timing bet: take on broad MFN exposure now for tariff cover that expires in 2029, or hold out and carry tariffs plus the mandatory Medicare models. With the tariff-relief application window closing on 12 June 2026, the sensible next step is to put real numbers on both paths rather than argue about the national total.
Related reading
Sources & Further Reading
- Council of Economic Advisers: Savings from Most-Favored-Nation (MFN) Drug Pricing Policy (May 2026)
- White House: Section 232 proclamation on pharmaceutical imports (April 2026)
- White House Fact Sheet: MFN developments (November 2025)
- Symaptics on GENEROUS: MFN Comes to Medicaid
- Symaptics on Decoding GLOBE & GUARD
Model your MFN exposure with SyMAP
SyMAP MFN turns assumptions like these into product-level numbers: second-lowest PPP-adjusted benchmarks, blended net-price gaps across every channel, and cross-program exposure across GENEROUS, GLOBE and GUARD.